No Data
Hai Chuang Pharmaceutical (688302.SH): The clinical trial application for HP568 tablets for the treatment of ER+/HER2- advanced breast cancer has been approved by the USA FDA.
Haichuang Pharmaceutical (688302.SH) announced that the company has received approval from the USA Food and Drug Administration (referred to as "FDA"...)
Third Quarter Report 2024
Hinova Pharmaceuticals Gets Regulatory Approval to Conduct Breast Cancer Clinical Trial
Haisco Pharmaceutical (688302.SH): Yingchuang Power has cumulatively reduced its shareholding by 1%.
GeLongHui, October 14th | HaiChuang Pharmaceutical (688302.SH) announced that the company recently received a notice from YingChuang Power regarding the expiration of the shareholding reduction plan period and the results of the reduction. As of October 14, 2024, the current shareholding reduction plan period has expired. During the implementation of this shareholding reduction plan, YingChuang Power has cumulatively reduced 990,150 shares of the company's stock, accounting for 1.00% of the total share capital of the company.
Hinova Pharmaceuticals Inc. (SHSE:688302) Surges 23%; Individual Investors Who Own 33% Shares Profited Along With Institutions
Half-year report for the year 2024.
No Data
